SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-23-049299
Filing Date
2023-04-25
Accepted
2023-04-25 08:01:23
Documents
19

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm231848d2_def14a.htm   iXBRL DEF 14A 1309115
6 GRAPHIC bc_paidvsyearendcash-4c.jpg GRAPHIC 175337
7 GRAPHIC bc_paidvsnetloss-4c.jpg GRAPHIC 160383
8 GRAPHIC px_01page-bw.jpg GRAPHIC 952084
9 GRAPHIC px_02page-4c.jpg GRAPHIC 637257
10 GRAPHIC bc_paidvstsr-4c.jpg GRAPHIC 168620
  Complete submission text file 0001104659-23-049299.txt   6882382

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cldx-20221231.xsd EX-101.SCH 9255
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cldx-20221231_def.xml EX-101.DEF 4402
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cldx-20221231_lab.xml EX-101.LAB 17100
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cldx-20221231_pre.xml EX-101.PRE 3384
13 EXTRACTED XBRL INSTANCE DOCUMENT tm231848d2_def14a_htm.xml XML 171142
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-15006 | Film No.: 23841804
SIC: 2835 In Vitro & In Vivo Diagnostic Substances